SVB Leerink Analyst Recommendations & Stock Picks

Name: Community Performance Rating
Item: SVB Leerink
Rating: 2.7
Author: MarketBeat

This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at SVB Leerink. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by SVB Leerink.

Company	Current Price	Rating Date	Action	Brokerage	Analyst	Rating	Price Target	Impact on Price	Details
SYBX Synlogic	$1.77 -48.7%	2/9/2024	Reiterated by	SVB Leerink	-	Outperform -> Market Perform		Low	View details for SVB Leerink rating of Synlogic (NASDAQ:SYBX) on 2/9/2024
AMGN Amgen	$291.12 -1.3%	2/7/2024	Downgraded by	SVB Leerink	-	Outperform -> Market Perform	$324.00 -> $318.00	Low	View details for SVB Leerink rating of Amgen (NASDAQ:AMGN) on 2/7/2024
UTHR United Therapeutics	$212.34 +0.3%	2/5/2024	Initiated by	SVB Leerink	-	Outperform	$330.00	Low	View details for SVB Leerink rating of United Therapeutics (NASDAQ:UTHR) on 2/5/2024
TSVT 2seventy bio	$5.99	1/31/2024	Upgraded by	SVB Leerink	-	Market Perform -> Outperform	$5.00 -> $18.00	Low	View details for SVB Leerink rating of 2seventy bio (NASDAQ:TSVT) on 1/31/2024
NPCE NeuroPace	$16.41 -3.0%	1/30/2024	Initiated by	SVB Leerink	-	Outperform	$22.00	Low	View details for SVB Leerink rating of NeuroPace (NASDAQ:NPCE) on 1/30/2024
IMNM Immunome	$23.11 -1.6%	1/29/2024	Initiated by	SVB Leerink	-	Outperform	$30.00	Low	View details for SVB Leerink rating of Immunome (NASDAQ:IMNM) on 1/29/2024
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
PYXS Pyxis Oncology	$4.48 +20.8%	1/23/2024	Initiated by	SVB Leerink	-	Outperform	$12.00	Low	View details for SVB Leerink rating of Pyxis Oncology (NASDAQ:PYXS) on 1/23/2024
AXNX Axonics	$67.95	1/12/2024	Reiterated by	SVB Leerink	-	Outperform -> Market Perform	$71.00	Low	View details for SVB Leerink rating of Axonics (NASDAQ:AXNX) on 1/12/2024
AGL agilon health	$6.82 -3.8%	1/8/2024	Downgraded by	SVB Leerink	-	Outperform -> Market Perform		Low	View details for SVB Leerink rating of agilon health (NYSE:AGL) on 1/8/2024
ALVR AlloVir	$0.72 +7.0%	12/22/2023	Downgraded by	SVB Leerink	-	Outperform -> Market Perform		Low	View details for SVB Leerink rating of AlloVir (NASDAQ:ALVR) on 12/22/2023
WVE Wave Life Sciences	$4.10 +1.0%	12/19/2023	Upgraded by	SVB Leerink	-	Market Perform -> Outperform	$5.00 -> $12.00	Low	View details for SVB Leerink rating of Wave Life Sciences (NASDAQ:WVE) on 12/19/2023
RPHM Reneo Pharmaceuticals	$1.74 +5.5%	12/15/2023	Reiterated by	SVB Leerink	-	Outperform -> Market Perform		Low	View details for SVB Leerink rating of Reneo Pharmaceuticals (NASDAQ:RPHM) on 12/15/2023
INCY Incyte	$57.66 +0.5%	12/13/2023	Upgraded by	SVB Leerink	-	Market Perform -> Outperform	$78.00	Low	View details for SVB Leerink rating of Incyte (NASDAQ:INCY) on 12/13/2023
NBTX Nanobiotix	$7.39 -1.6%	12/8/2023	Initiated by	SVB Leerink	-	Outperform	$11.00	Low	View details for SVB Leerink rating of Nanobiotix (NASDAQ:NBTX) on 12/8/2023
TNYA Tenaya Therapeutics	$5.68 +10.7%	11/30/2023	Initiated by	SVB Leerink	-	Outperform	$7.00	Low	View details for SVB Leerink rating of Tenaya Therapeutics (NASDAQ:TNYA) on 11/30/2023
LXEO Lexeo Therapeutics	$16.54 -1.7%	11/28/2023	Initiated by	SVB Leerink	-	Outperform	$19.00	Low	View details for SVB Leerink rating of Lexeo Therapeutics (NASDAQ:LXEO) on 11/28/2023
ABVX ABIVAX Société Anonyme	$12.50 -2.1%	11/14/2023	Initiated by	SVB Leerink	-	Outperform	$20.00	Low	View details for SVB Leerink rating of ABIVAX Société Anonyme (NASDAQ:ABVX) on 11/14/2023
MRTX Mirati Therapeutics	$58.70 -0.2%	11/7/2023	Reiterated by	SVB Leerink	-	Outperform -> Market Perform	$78.00 -> $58.00	Low	View details for SVB Leerink rating of Mirati Therapeutics (NASDAQ:MRTX) on 11/7/2023
ZNTL Zentalis Pharmaceuticals	$11.50 -0.3%	11/7/2023	Downgraded by	SVB Leerink	-	Outperform -> Market Perform	$15.00	Low	View details for SVB Leerink rating of Zentalis Pharmaceuticals (NASDAQ:ZNTL) on 11/7/2023
TSVT 2seventy bio	$5.99	10/30/2023	Downgraded by	SVB Leerink	-	Outperform -> Market Perform	$6.00	Low	View details for SVB Leerink rating of 2seventy bio (NASDAQ:TSVT) on 10/30/2023
BEAM Beam Therapeutics	$29.05 +3.3%	10/20/2023	Downgraded by	SVB Leerink	-	Outperform -> Market Perform	$75.00 -> $20.00	Low	View details for SVB Leerink rating of Beam Therapeutics (NASDAQ:BEAM) on 10/20/2023
FDMT 4D Molecular Therapeutics	$28.63 +6.4%	10/18/2023	Upgraded by	SVB Leerink	-	Market Perform -> Outperform	$24.00	Low	View details for SVB Leerink rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 10/18/2023
AXGN AxoGen	$9.88 +0.1%	10/16/2023	Initiated by	SVB Leerink	-	Outperform	$9.00	Low	View details for SVB Leerink rating of AxoGen (NASDAQ:AXGN) on 10/16/2023
AXNX Axonics	$67.95	10/16/2023	Initiated by	SVB Leerink	-	Outperform	$70.00	Low	View details for SVB Leerink rating of Axonics (NASDAQ:AXNX) on 10/16/2023
PRCT PROCEPT BioRobotics	$49.94 +0.9%	10/16/2023	Initiated by	SVB Leerink	-	Outperform	$37.00	Low	View details for SVB Leerink rating of PROCEPT BioRobotics (NASDAQ:PRCT) on 10/16/2023
DXCM DexCom	$120.47 -5.2%	10/16/2023	Initiated by	SVB Leerink	-	Outperform	$110.00	Low	View details for SVB Leerink rating of DexCom (NASDAQ:DXCM) on 10/16/2023
EW Edwards Lifesciences	$85.01 -0.9%	10/16/2023	Initiated by	SVB Leerink	-	Market Perform	$75.00	Low	View details for SVB Leerink rating of Edwards Lifesciences (NYSE:EW) on 10/16/2023
SWAV Shockwave Medical	$233.71 -1.3%	10/16/2023	Initiated by	SVB Leerink	-	Outperform	$263.00	Low	View details for SVB Leerink rating of Shockwave Medical (NASDAQ:SWAV) on 10/16/2023
INSP Inspire Medical Systems	$194.87 -3.5%	10/16/2023	Initiated by	SVB Leerink	-	Market Perform	$159.00	Low	View details for SVB Leerink rating of Inspire Medical Systems (NYSE:INSP) on 10/16/2023
TNDM Tandem Diabetes Care	$23.30 +0.6%	10/16/2023	Initiated by	SVB Leerink	-	Market Perform	$21.00	Low	View details for SVB Leerink rating of Tandem Diabetes Care (NASDAQ:TNDM) on 10/16/2023
ISRG Intuitive Surgical	$388.22 +0.3%	10/16/2023	Initiated by	SVB Leerink	-	Outperform	$342.00	Low	View details for SVB Leerink rating of Intuitive Surgical (NASDAQ:ISRG) on 10/16/2023
VCEL Vericel	$46.78 +2.0%	10/16/2023	Initiated by	SVB Leerink	-	Outperform	$42.00	Low	View details for SVB Leerink rating of Vericel (NASDAQ:VCEL) on 10/16/2023
PODD Insulet	$192.55 -2.1%	10/16/2023	Initiated by	SVB Leerink	-	Outperform	$184.00	Low	View details for SVB Leerink rating of Insulet (NASDAQ:PODD) on 10/16/2023
AMGN Amgen	$291.12 -1.3%	10/11/2023	Upgraded by	SVB Leerink	-	Market Perform -> Outperform	$267.00 -> $318.00	Low	View details for SVB Leerink rating of Amgen (NASDAQ:AMGN) on 10/11/2023
NBIX Neurocrine Biosciences	$132.30 -1.6%	10/6/2023	Target Raised by	SVB Leerink	Analyst M. Goodman		$125.00 -> $135.00	Low	View details for SVB Leerink rating of Neurocrine Biosciences (NASDAQ:NBIX) on 10/6/2023
GPCR Structure Therapeutics	$49.00 +4.3%	9/29/2023	Target Raised by	SVB Leerink	-		$46.00 -> $97.00	Low	View details for SVB Leerink rating of Structure Therapeutics (NASDAQ:GPCR) on 9/29/2023
SPRY ARS Pharmaceuticals	$7.08 +9.1%	9/21/2023	Downgraded by	SVB Leerink	-	Outperform -> Market Perform		Low	View details for SVB Leerink rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 9/21/2023
PTCT PTC Therapeutics	$25.51 +1.0%	9/18/2023	Target Lowered by	SVB Leerink	Analyst J. Schwartz		$44.00 -> $30.00	Low	View details for SVB Leerink rating of PTC Therapeutics (NASDAQ:PTCT) on 9/18/2023
SPRB Spruce Biosciences	$4.33 +8.8%	9/8/2023	Upgraded by	SVB Leerink	-	Market Perform -> Outperform	$3.00 -> $9.00	Low	View details for SVB Leerink rating of Spruce Biosciences (NASDAQ:SPRB) on 9/8/2023
GLTO Galecto	$0.62 +1.5%	8/15/2023	Reiterated by	SVB Leerink	-	Outperform -> Market Perform	$13.00 -> $2.00	Low	View details for SVB Leerink rating of Galecto (NASDAQ:GLTO) on 8/15/2023

DSGN Design Therapeutics	$2.32 +1.3%	8/15/2023	Reiterated by	SVB Leerink	-	Outperform -> Market Perform	$6.00	Low	View details for SVB Leerink rating of Design Therapeutics (NASDAQ:DSGN) on 8/15/2023
CYTK Cytokinetics	$76.94 -2.5%	8/15/2023	Initiated by	SVB Leerink	-	Outperform	$58.00	Low	View details for SVB Leerink rating of Cytokinetics (NASDAQ:CYTK) on 8/15/2023
EXEL Exelixis	$20.22 +0.2%	8/8/2023	Initiated by	SVB Leerink	-	Market Perform	$18.00	Low	View details for SVB Leerink rating of Exelixis (NASDAQ:EXEL) on 8/8/2023
IDYA IDEAYA Biosciences	$45.89 +2.4%	8/8/2023	Initiated by	SVB Leerink	-	Outperform	$33.00	Low	View details for SVB Leerink rating of IDEAYA Biosciences (NASDAQ:IDYA) on 8/8/2023
NUVL Nuvalent	$82.45 +2.3%	8/8/2023	Initiated by	SVB Leerink	-	Market Perform	$42.00	Low	View details for SVB Leerink rating of Nuvalent (NASDAQ:NUVL) on 8/8/2023
NVCR NovoCure	$15.31 +3.1%	8/4/2023	Initiated by	SVB Leerink	-	Outperform	$51.00	Low	View details for SVB Leerink rating of NovoCure (NASDAQ:NVCR) on 8/4/2023
BLTE Belite Bio	$47.55 +3.7%	7/26/2023	Reiterated by	SVB Leerink	Analyst M. Goodman	Outperform	$25.00	Low	View details for SVB Leerink rating of Belite Bio (NASDAQ:BLTE) on 7/26/2023
NBIX Neurocrine Biosciences	$132.30 -1.6%	7/24/2023	Upgraded by	SVB Leerink	Analyst M. Goodman	Market Perform -> Outperform		Low	View details for SVB Leerink rating of Neurocrine Biosciences (NASDAQ:NBIX) on 7/24/2023
CYRX Cryoport	$15.89 +1.0%	7/13/2023	Downgraded by	SVB Leerink	Analyst P. Souda	Outperform -> Market Perform		Low	View details for SVB Leerink rating of Cryoport (NASDAQ:CYRX) on 7/13/2023
BMY Bristol-Myers Squibb	$49.81 +2.3%	7/10/2023	Reiterated by	SVB Leerink	Analyst D. Risinger	Market Perform		Low	View details for SVB Leerink rating of Bristol-Myers Squibb (NYSE:BMY) on 7/10/2023
EHAB Enhabit	$8.93 +0.3%	6/20/2023	Reiterated by	SVB Leerink	Analyst W. Mayo	Underperform		Low	View details for SVB Leerink rating of Enhabit (NYSE:EHAB) on 6/20/2023
OCS Oculis	$12.70 +0.9%	6/12/2023	Reiterated by	SVB Leerink	Analyst M. Goodman	Outperform		Low	View details for SVB Leerink rating of Oculis (NASDAQ:OCS) on 6/12/2023
BPMC Blueprint Medicines	$76.54 +3.2%	6/5/2023	Downgraded by	SVB Leerink	Analyst A. Berens	Market Perform -> Underperform		Low	View details for SVB Leerink rating of Blueprint Medicines (NASDAQ:BPMC) on 6/5/2023
ELEV Elevation Oncology	$3.00 +3.4%	5/30/2023	Upgraded by	SVB Leerink	Analyst A. Berens	Market Perform -> Outperform		Low	View details for SVB Leerink rating of Elevation Oncology (NASDAQ:ELEV) on 5/30/2023
RAIN Rain Oncology	$1.21 -1.6%	5/22/2023	Downgraded by	SVB Leerink	Analyst F. Khurshid	Outperform -> Market Perform		Low	View details for SVB Leerink rating of Rain Oncology (NASDAQ:RAIN) on 5/22/2023
BOLT Bolt Biotherapeutics	$1.09 +2.8%	5/12/2023	Upgraded by	SVB Leerink	Analyst D. Graybosch	Market Perform -> Outperform		Low	View details for SVB Leerink rating of Bolt Biotherapeutics (NASDAQ:BOLT) on 5/12/2023
ARWR Arrowhead Pharmaceuticals	$32.56 +5.5%	5/12/2023	Downgraded by	SVB Leerink	Analyst M. Foroohar	Outperform -> Market Perform		Low	View details for SVB Leerink rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 5/12/2023
DHR Danaher	$242.95 -1.2%	5/1/2023	Reiterated by	SVB Leerink	Analyst P. Souda	Outperform		Low	View details for SVB Leerink rating of Danaher (NYSE:DHR) on 5/1/2023
PRTA Prothena	$28.38 +3.5%	4/24/2023	Reiterated by	SVB Leerink	Analyst R. Li	Outperform		Low	View details for SVB Leerink rating of Prothena (NASDAQ:PRTA) on 4/24/2023
GNFT Genfit	$3.67 +3.1%	4/14/2023	Reiterated by	SVB Leerink	Analyst T. Smith	Outperform		Low	View details for SVB Leerink rating of Genfit (NASDAQ:GNFT) on 4/14/2023
CNTB Connect Biopharma	$1.40 +26.1%	4/12/2023	Reiterated by	SVB Leerink	Analyst T. Smith	Outperform		Low	View details for SVB Leerink rating of Connect Biopharma (NASDAQ:CNTB) on 4/12/2023
ARWR Arrowhead Pharmaceuticals	$32.56 +5.5%	4/12/2023	Upgraded by	SVB Leerink	Analyst M. Foroohar	Market Perform -> Outperform		Low	View details for SVB Leerink rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 4/12/2023
CORT Corcept Therapeutics	$23.01 +2.3%	4/11/2023	Reiterated by	SVB Leerink	Analyst R. Ruiz	Market Perform	$25.00	Low	View details for SVB Leerink rating of Corcept Therapeutics (NASDAQ:CORT) on 4/11/2023
ACLX Arcellx	$64.89 +5.4%	3/30/2023	Target Raised by	SVB Leerink	-	Outperform	$35.00 -> $39.00	Low	View details for SVB Leerink rating of Arcellx (NASDAQ:ACLX) on 3/30/2023
ABT Abbott Laboratories	$111.81 -0.6%	3/31/2023	Target Raised by	SVB Leerink	-	Market Perform	$90.00 -> $102.00	Low	View details for SVB Leerink rating of Abbott Laboratories (NYSE:ABT) on 3/31/2023
REGN Regeneron Pharmaceuticals	$953.42 +0.7%	3/27/2023	Upgraded by	SVB Leerink	Analyst D. Risinger	Market Perform -> Outperform		Low	View details for SVB Leerink rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 3/27/2023
RAIN Rain Oncology	$1.21 -1.6%	3/21/2023	Reiterated by	SVB Leerink	Analyst F. Khurshid	Outperform	$11.00	Low	View details for SVB Leerink rating of Rain Oncology (NASDAQ:RAIN) on 3/21/2023
PTCT PTC Therapeutics	$25.51 +1.0%	3/17/2023	Reiterated by	SVB Leerink	Analyst J. Schwartz	Market Perform	$48.00	Low	View details for SVB Leerink rating of PTC Therapeutics (NASDAQ:PTCT) on 3/17/2023
CNTA Centessa Pharmaceuticals	$9.26 +24.1%	3/17/2023	Reiterated by	SVB Leerink	Analyst D. Risinger	Outperform	$6.00	Low	View details for SVB Leerink rating of Centessa Pharmaceuticals (NASDAQ:CNTA) on 3/17/2023
HALO Halozyme Therapeutics	$35.49 +0.7%	3/16/2023	Downgraded by	SVB Leerink	Analyst D. Risinger	Outperform -> Market Perform	$42.00	Low	View details for SVB Leerink rating of Halozyme Therapeutics (NASDAQ:HALO) on 3/16/2023
MORF Morphic	$39.70 +2.6%	3/8/2023	Target Raised by	SVB Leerink	-	Outperform	$45.00 -> $56.00	Low	View details for SVB Leerink rating of Morphic (NASDAQ:MORF) on 3/8/2023
ARGX argenx	$401.48 +1.7%	3/3/2023	Target Raised by	SVB Leerink	-	Outperform	$430.00 -> $435.00	Low	View details for SVB Leerink rating of argenx (NASDAQ:ARGX) on 3/3/2023
GPCR Structure Therapeutics	$49.00 +4.3%	2/28/2023	Reiterated by	SVB Leerink	Analyst D. Risinger	Outperform		Low	View details for SVB Leerink rating of Structure Therapeutics (NASDAQ:GPCR) on 2/28/2023
CGEN Compugen	$2.14	2/28/2023	Reiterated by	SVB Leerink	Analyst D. Graybosch	Outperform		Low	View details for SVB Leerink rating of Compugen (NASDAQ:CGEN) on 2/28/2023
IRON Disc Medicine	$68.29 +2.3%	2/28/2023	Reiterated by	SVB Leerink	Analyst T. Smith	Outperform	$36.00	Low	View details for SVB Leerink rating of Disc Medicine (NASDAQ:IRON) on 2/28/2023
XNCR Xencor	$19.42 +4.1%	2/23/2023	Reiterated by	SVB Leerink	Analyst J. Chang	Outperform		Low	View details for SVB Leerink rating of Xencor (NASDAQ:XNCR) on 2/23/2023
MRNA Moderna	$87.41 -6.7%	2/24/2023	Downgraded by	SVB Leerink	Analyst M. Foroohar	Market Perform -> Underperform	$111.00 -> $93.00	Low	View details for SVB Leerink rating of Moderna (NASDAQ:MRNA) on 2/24/2023
NKTR Nektar Therapeutics	$0.71 +3.6%	2/24/2023	Target Lowered by	SVB Leerink	-	Market Perform	$5.00 -> $3.00	N/A	View details for SVB Leerink rating of Nektar Therapeutics (NASDAQ:NKTR) on 2/24/2023
BPMC Blueprint Medicines	$76.54 +3.2%	2/24/2023	Target Lowered by	SVB Leerink	-	Market Perform	$45.00 -> $38.00	Low	View details for SVB Leerink rating of Blueprint Medicines (NASDAQ:BPMC) on 2/24/2023
IONS Ionis Pharmaceuticals	$51.40 +2.8%	2/23/2023	Target Lowered by	SVB Leerink	-	Market Perform	$34.00 -> $27.00	Low	View details for SVB Leerink rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 2/23/2023
TDOC Teladoc Health	$20.60 +1.1%	2/23/2023	Upgraded by	SVB Leerink	Analyst S. Davis	Market Perform -> Outperform	$34.00	Low	View details for SVB Leerink rating of Teladoc Health (NYSE:TDOC) on 2/23/2023
ABBV AbbVie	$174.08 -0.4%	2/10/2023	Upgraded by	SVB Leerink	Analyst D. Risinger	Underperform -> Market Perform	$135.00 -> $153.00	Low	View details for SVB Leerink rating of AbbVie (NYSE:ABBV) on 2/10/2023
ENTA Enanta Pharmaceuticals	$12.34 -0.2%	2/9/2023	Reiterated by	SVB Leerink	-	Market Perform	$49.00	Low	View details for SVB Leerink rating of Enanta Pharmaceuticals (NASDAQ:ENTA) on 2/9/2023
CBAY CymaBay Therapeutics	$25.69 +2.9%	2/8/2023	Target Raised by	SVB Leerink	-	Outperform	$10.00 -> $12.00	Low	View details for SVB Leerink rating of CymaBay Therapeutics (NASDAQ:CBAY) on 2/8/2023
CNTB Connect Biopharma	$1.40 +26.1%	2/8/2023	Target Lowered by	SVB Leerink	-	Outperform	$9.00 -> $7.00	Low	View details for SVB Leerink rating of Connect Biopharma (NASDAQ:CNTB) on 2/8/2023
EQ Equillium	$1.54 +1.3%	2/8/2023	Target Lowered by	SVB Leerink	-	Outperform	$12.00 -> $7.00	Low	View details for SVB Leerink rating of Equillium (NASDAQ:EQ) on 2/8/2023
CI The Cigna Group	$334.93 +0.8%	2/8/2023	Target Raised by	SVB Leerink	-	Market Perform	$309.00 -> $335.00	Low	View details for SVB Leerink rating of The Cigna Group (NYSE:CI) on 2/8/2023
PINC Premier	$21.24 +0.9%	2/8/2023	Target Lowered by	SVB Leerink	-	Outperform	$46.00 -> $42.00	Low	View details for SVB Leerink rating of Premier (NASDAQ:PINC) on 2/8/2023
ILMN Illumina	$137.84 -3.8%	2/8/2023	Target Raised by	SVB Leerink	Analyst P. Souda	Outperform	$249.00 -> $250.00	Low	View details for SVB Leerink rating of Illumina (NASDAQ:ILMN) on 2/8/2023
VRTX Vertex Pharmaceuticals	$422.91 0.0%	2/8/2023	Target Lowered by	SVB Leerink	-	Outperform	$374.00 -> $365.00	Low	View details for SVB Leerink rating of Vertex Pharmaceuticals (NASDAQ:VRTX) on 2/8/2023

INCY Incyte	$57.66 +0.5%	2/8/2023	Reiterated by	SVB Leerink	-	Underperform	$63.00	Low	View details for SVB Leerink rating of Incyte (NASDAQ:INCY) on 2/8/2023
DCPH Deciphera Pharmaceuticals	$15.73 +11.0%	2/7/2023	Target Raised by	SVB Leerink	-	Outperform	$28.00 -> $30.00	Low	View details for SVB Leerink rating of Deciphera Pharmaceuticals (NASDAQ:DCPH) on 2/7/2023
GMAB Genmab A/S	$27.84 +0.2%	2/6/2023	Target Raised by	SVB Leerink	-	Market Perform	$33.00 -> $36.00	Low	View details for SVB Leerink rating of Genmab A/S (NASDAQ:GMAB) on 2/6/2023
FDMT 4D Molecular Therapeutics	$28.63 +6.4%	2/6/2023	Target Lowered by	SVB Leerink	Analyst M. Foroohar	Market Perform	$15.00 -> $14.00	Low	View details for SVB Leerink rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 2/6/2023
IMVT Immunovant	$35.50 +0.7%	2/6/2023	Target Raised by	SVB Leerink	-	Outperform	$14.00 -> $21.00	Low	View details for SVB Leerink rating of Immunovant (NASDAQ:IMVT) on 2/6/2023
SGEN Seagen	$228.74 -0.1%	2/6/2023	Downgraded by	SVB Leerink	Analyst Andrew Berens	Outperform -> Market Perform	$162.00 -> $141.00	Low	View details for SVB Leerink rating of Seagen (NASDAQ:SGEN) on 2/6/2023
REGN Regeneron Pharmaceuticals	$953.42 +0.7%	2/6/2023	Target Raised by	SVB Leerink	Analyst D. Risinger	Market Perform	$770.00 -> $834.00	Low	View details for SVB Leerink rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 2/6/2023
GILD Gilead Sciences	$73.67 -0.2%	2/3/2023	Target Raised by	SVB Leerink	Analyst D. Risinger	Market Perform	$81.00 -> $91.00	Low	View details for SVB Leerink rating of Gilead Sciences (NASDAQ:GILD) on 2/3/2023
TECH Bio-Techne	$67.95 0.0%	2/3/2023	Target Lowered by	SVB Leerink	-	Outperform	$125.00 -> $110.00	Low	View details for SVB Leerink rating of Bio-Techne (NASDAQ:TECH) on 2/3/2023
BMRN BioMarin Pharmaceutical	$88.46 +0.4%	2/3/2023	Target Raised by	SVB Leerink	-	Outperform	$122.00 -> $130.00	Low	View details for SVB Leerink rating of BioMarin Pharmaceutical (NASDAQ:BMRN) on 2/3/2023
IONS Ionis Pharmaceuticals	$51.40 +2.8%	2/3/2023	Target Raised by	SVB Leerink	-	Market Perform	$33.00 -> $34.00	Low	View details for SVB Leerink rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 2/3/2023
MRK Merck & Co., Inc.	$125.45 -0.9%	2/3/2023	Target Raised by	SVB Leerink	-	Outperform	$120.00 -> $122.00	Low	View details for SVB Leerink rating of Merck & Co., Inc. (NYSE:MRK) on 2/3/2023
KALV KalVista Pharmaceuticals	$16.00 +7.4%	2/3/2023	Target Lowered by	SVB Leerink	-	Outperform	$30.00 -> $20.00	Low	View details for SVB Leerink rating of KalVista Pharmaceuticals (NASDAQ:KALV) on 2/3/2023
TMO Thermo Fisher Scientific	$550.75 0.0%	2/2/2023	Target Raised by	SVB Leerink	-	Outperform	$620.00 -> $630.00	Low	View details for SVB Leerink rating of Thermo Fisher Scientific (NYSE:TMO) on 2/2/2023
HOLX Hologic	$73.44 +0.0%	2/2/2023	Target Raised by	SVB Leerink	-	Outperform	$90.00 -> $93.00	Low	View details for SVB Leerink rating of Hologic (NASDAQ:HOLX) on 2/2/2023
AMGN Amgen	$291.12 -1.3%	2/2/2023	Target Lowered by	SVB Leerink	-	Market Perform	$282.00 -> $267.00	Low	View details for SVB Leerink rating of Amgen (NASDAQ:AMGN) on 2/2/2023
PFE Pfizer	$27.56 0.0%	2/1/2023	Target Lowered by	SVB Leerink	Analyst David Risinger	Market Perform	$49.00 -> $48.00	Low	View details for SVB Leerink rating of Pfizer (NYSE:PFE) on 2/1/2023
OPRX OptimizeRx	$15.31 -1.2%	1/27/2023	Reiterated by	SVB Leerink	Analyst S. Davis	Outperform		Low	View details for SVB Leerink rating of OptimizeRx (NASDAQ:OPRX) on 1/27/2023
OMCL Omnicell	$27.41 -5.8%	1/27/2023	Reiterated by	SVB Leerink	Analyst S. Davis	Market Perform		Low	View details for SVB Leerink rating of Omnicell (NASDAQ:OMCL) on 1/27/2023
IQV IQVIA	$218.20 +0.6%	1/27/2023	Reiterated by	SVB Leerink	Analyst S. Davis	Outperform		Low	View details for SVB Leerink rating of IQVIA (NYSE:IQV) on 1/27/2023
CPSI Computer Programs and Systems	$10.22 -2.0%	1/27/2023	Reiterated by	SVB Leerink	Analyst S. Davis	Outperform		Low	View details for SVB Leerink rating of Computer Programs and Systems (NASDAQ:CPSI) on 1/27/2023
DNLI Denali Therapeutics	$18.05 +4.9%	1/30/2023	Reiterated by	SVB Leerink	Analyst M. Goodman	Outperform	$50.00	Low	View details for SVB Leerink rating of Denali Therapeutics (NASDAQ:DNLI) on 1/30/2023
AVIR Atea Pharmaceuticals	$4.26	1/27/2023	Target Lowered by	SVB Leerink	-	Market Perform	$8.00 -> $6.00	Low	View details for SVB Leerink rating of Atea Pharmaceuticals (NASDAQ:AVIR) on 1/27/2023
ENTA Enanta Pharmaceuticals	$12.34 -0.2%	1/27/2023	Target Lowered by	SVB Leerink	-	Market Perform	$50.00 -> $49.00	Low	View details for SVB Leerink rating of Enanta Pharmaceuticals (NASDAQ:ENTA) on 1/27/2023
SCPH scPharmaceuticals	$5.38 +5.3%	1/27/2023	Target Raised by	SVB Leerink	Analyst R. Ruiz	Outperform	$12.00 -> $13.00	Low	View details for SVB Leerink rating of scPharmaceuticals (NASDAQ:SCPH) on 1/27/2023
VIR Vir Biotechnology	$9.29 +0.7%	1/27/2023	Target Lowered by	SVB Leerink	Analyst R. Ruiz	Outperform	$45.00 -> $43.00	Low	View details for SVB Leerink rating of Vir Biotechnology (NASDAQ:VIR) on 1/27/2023
XERS Xeris Biopharma	$2.87 +5.1%	1/27/2023	Target Lowered by	SVB Leerink	-	Outperform	$6.00 -> $5.00	Low	View details for SVB Leerink rating of Xeris Biopharma (NASDAQ:XERS) on 1/27/2023
ELV Elevance Health	$506.08 +0.8%	1/26/2023	Reiterated by	SVB Leerink	Analyst W. Mayo	Outperform	$580.00	Low	View details for SVB Leerink rating of Elevance Health (NYSE:ELV) on 1/26/2023
PLRX Pliant Therapeutics	$16.93 +3.9%	1/24/2023	Target Raised by	SVB Leerink	-	Outperform	$33.00 -> $45.00	Low	View details for SVB Leerink rating of Pliant Therapeutics (NASDAQ:PLRX) on 1/24/2023
BHVN Biohaven	$48.55 +3.5%	1/24/2023	Reiterated by	SVB Leerink	Analyst M. Goodman	Outperform	$24.00	Low	View details for SVB Leerink rating of Biohaven (NYSE:BHVN) on 1/24/2023
MRK Merck & Co., Inc.	$125.45 -0.9%	1/23/2023	Target Raised by	SVB Leerink	-	Outperform	$112.00 -> $120.00	Low	View details for SVB Leerink rating of Merck & Co., Inc. (NYSE:MRK) on 1/23/2023
MRNS Marinus Pharmaceuticals	$10.10 +1.1%	1/23/2023	Target Lowered by	SVB Leerink	-	Outperform	$27.00 -> $23.00	Low	View details for SVB Leerink rating of Marinus Pharmaceuticals (NASDAQ:MRNS) on 1/23/2023
RLMD Relmada Therapeutics	$5.45 +4.0%	1/23/2023	Target Lowered by	SVB Leerink	-	Outperform	$42.00 -> $10.00	Low	View details for SVB Leerink rating of Relmada Therapeutics (NASDAQ:RLMD) on 1/23/2023
ALNY Alnylam Pharmaceuticals	$170.03 +0.3%	1/23/2023	Target Lowered by	SVB Leerink	-	Market Perform	$144.00 -> $143.00	Low	View details for SVB Leerink rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 1/23/2023
ALVR AlloVir	$0.72 +7.0%	1/23/2023	Target Lowered by	SVB Leerink	-	Outperform	$25.00 -> $19.00	Low	View details for SVB Leerink rating of AlloVir (NASDAQ:ALVR) on 1/23/2023
BBIO BridgeBio Pharma	$34.47 +4.6%	1/23/2023	Target Lowered by	SVB Leerink	-	Outperform	$23.00 -> $19.00	Low	View details for SVB Leerink rating of BridgeBio Pharma (NASDAQ:BBIO) on 1/23/2023
BEAM Beam Therapeutics	$29.05 +3.3%	1/23/2023	Target Lowered by	SVB Leerink	-	Outperform	$81.00 -> $77.00	Low	View details for SVB Leerink rating of Beam Therapeutics (NASDAQ:BEAM) on 1/23/2023
BLUE bluebird bio	$1.03 -1.9%	1/23/2023	Target Lowered by	SVB Leerink	-	Market Perform	$9.00 -> $8.00	Low	View details for SVB Leerink rating of bluebird bio (NASDAQ:BLUE) on 1/23/2023
EDIT Editas Medicine	$7.45 +3.9%	1/23/2023	Target Raised by	SVB Leerink	Analyst R. Bienkowski	Market Perform	$6.00 -> $7.00	Low	View details for SVB Leerink rating of Editas Medicine (NASDAQ:EDIT) on 1/23/2023
IONS Ionis Pharmaceuticals	$51.40 +2.8%	1/23/2023	Target Raised by	SVB Leerink	-	Market Perform	$32.00 -> $33.00	Low	View details for SVB Leerink rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 1/23/2023
NTLA Intellia Therapeutics	$28.23 +2.8%	1/23/2023	Target Lowered by	SVB Leerink	-	Outperform	$86.00 -> $84.00	Low	View details for SVB Leerink rating of Intellia Therapeutics (NASDAQ:NTLA) on 1/23/2023
RCKT Rocket Pharmaceuticals	$29.50 +0.8%	1/23/2023	Target Lowered by	SVB Leerink	-	Outperform	$50.00 -> $49.00	Low	View details for SVB Leerink rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 1/23/2023
RGNX REGENXBIO	$16.21 -0.5%	1/23/2023	Target Lowered by	SVB Leerink	-	Market Perform	$15.00 -> $14.00	Low	View details for SVB Leerink rating of REGENXBIO (NASDAQ:RGNX) on 1/23/2023
RXRX Recursion Pharmaceuticals	$10.09 +1.9%	1/23/2023	Target Lowered by	SVB Leerink	-	Market Perform	$9.00 -> $8.00	Low	View details for SVB Leerink rating of Recursion Pharmaceuticals (NASDAQ:RXRX) on 1/23/2023
SRPT Sarepta Therapeutics	$126.87 -0.4%	1/20/2023	Reiterated by	SVB Leerink	-	Outperform	$160.00	Low	View details for SVB Leerink rating of Sarepta Therapeutics (NASDAQ:SRPT) on 1/20/2023
ZYME Zymeworks	$11.15 -2.8%	1/20/2023	Target Raised by	SVB Leerink	Analyst A. Berens	Market Perform	$8.00 -> $10.00	Low	View details for SVB Leerink rating of Zymeworks (NYSE:ZYME) on 1/20/2023
SGEN Seagen	$228.74 -0.1%	1/20/2023	Target Raised by	SVB Leerink	Analyst Andrew Berens	Outperform	$160.00 -> $162.00	Low	View details for SVB Leerink rating of Seagen (NASDAQ:SGEN) on 1/20/2023
BGNE BeiGene	$146.98 +2.9%	1/20/2023	Target Raised by	SVB Leerink	-	Outperform	$236.00 -> $300.00	Low	View details for SVB Leerink rating of BeiGene (NASDAQ:BGNE) on 1/20/2023
JNJ Johnson & Johnson	$156.76 +0.2%	1/20/2023	Target Lowered by	SVB Leerink	-	Outperform	$194.00 -> $186.00	Low	View details for SVB Leerink rating of Johnson & Johnson (NYSE:JNJ) on 1/20/2023
MRNA Moderna	$87.41 -6.7%	1/18/2023	Target Raised by	SVB Leerink	Analyst M. Foroohar	Market Perform	$102.00 -> $111.00	Low	View details for SVB Leerink rating of Moderna (NASDAQ:MRNA) on 1/18/2023

EOLS Evolus	$13.70 +2.5%	1/19/2023	Target Raised by	SVB Leerink	-	Outperform	$18.00 -> $20.00	Low	View details for SVB Leerink rating of Evolus (NASDAQ:EOLS) on 1/19/2023
VRTX Vertex Pharmaceuticals	$422.91 0.0%	1/17/2023	Upgraded by	SVB Leerink	-	Market Perform -> Outperform	$374.00	Low	View details for SVB Leerink rating of Vertex Pharmaceuticals (NASDAQ:VRTX) on 1/17/2023
EXAS Exact Sciences	$60.64 -0.6%	1/12/2023	Target Raised by	SVB Leerink	-	Outperform	$70.00 -> $75.00	Low	View details for SVB Leerink rating of Exact Sciences (NASDAQ:EXAS) on 1/12/2023
HOLX Hologic	$73.44 +0.0%	1/12/2023	Target Raised by	SVB Leerink	-	Outperform	$85.00 -> $90.00	Low	View details for SVB Leerink rating of Hologic (NASDAQ:HOLX) on 1/12/2023
HALO Halozyme Therapeutics	$35.49 +0.7%	1/11/2023	Target Lowered by	SVB Leerink	-	Outperform	$62.00 -> $61.00	Low	View details for SVB Leerink rating of Halozyme Therapeutics (NASDAQ:HALO) on 1/11/2023
MIRM Mirum Pharmaceuticals	$27.98 +3.6%	1/10/2023	Target Lowered by	SVB Leerink	-	Outperform	$50.00 -> $39.00	Low	View details for SVB Leerink rating of Mirum Pharmaceuticals (NASDAQ:MIRM) on 1/10/2023
EDIT Editas Medicine	$7.45 +3.9%	1/10/2023	Target Lowered by	SVB Leerink	Analyst R. Bienkowski	Market Perform	$7.00 -> $6.00	Low	View details for SVB Leerink rating of Editas Medicine (NASDAQ:EDIT) on 1/10/2023
KPTI Karyopharm Therapeutics	$1.34 -11.3%	1/10/2023	Target Lowered by	SVB Leerink	-	Market Perform	$6.00 -> $5.00	Low	View details for SVB Leerink rating of Karyopharm Therapeutics (NASDAQ:KPTI) on 1/10/2023
TSVT 2seventy bio	$5.99	1/10/2023	Target Lowered by	SVB Leerink	-	Outperform	$41.00 -> $34.00	Low	View details for SVB Leerink rating of 2seventy bio (NASDAQ:TSVT) on 1/10/2023
VRDN Viridian Therapeutics	$18.52 +3.1%	1/9/2023	Target Raised by	SVB Leerink	-	Outperform	$40.00 -> $45.00	Low	View details for SVB Leerink rating of Viridian Therapeutics (NASDAQ:VRDN) on 1/9/2023
BLUE bluebird bio	$1.03 -1.9%	1/6/2023	Target Raised by	SVB Leerink	-	Market Perform	$8.00 -> $9.00	Low	View details for SVB Leerink rating of bluebird bio (NASDAQ:BLUE) on 1/6/2023
EXAS Exact Sciences	$60.64 -0.6%	1/6/2023	Target Raised by	SVB Leerink	-	Outperform	$60.00 -> $70.00	Low	View details for SVB Leerink rating of Exact Sciences (NASDAQ:EXAS) on 1/6/2023
HOLX Hologic	$73.44 +0.0%	1/6/2023	Target Raised by	SVB Leerink	-	Outperform	$78.00 -> $85.00	Low	View details for SVB Leerink rating of Hologic (NASDAQ:HOLX) on 1/6/2023
A Agilent Technologies	$133.34 -0.5%	1/6/2023	Target Raised by	SVB Leerink	-	Outperform	$160.00 -> $170.00	Low	View details for SVB Leerink rating of Agilent Technologies (NYSE:A) on 1/6/2023
ABCL AbCellera Biologics	$5.11 +1.8%	1/6/2023	Target Lowered by	SVB Leerink	-	Outperform	$20.00 -> $18.00	Low	View details for SVB Leerink rating of AbCellera Biologics (NASDAQ:ABCL) on 1/6/2023
MASS 908 Devices	$7.15 +0.1%	1/6/2023	Target Lowered by	SVB Leerink	-	Outperform	$25.00 -> $20.00	Low	View details for SVB Leerink rating of 908 Devices (NASDAQ:MASS) on 1/6/2023
RGEN Repligen	$205.00 +0.5%	1/6/2023	Target Lowered by	SVB Leerink	-	Outperform	$230.00 -> $200.00	Low	View details for SVB Leerink rating of Repligen (NASDAQ:RGEN) on 1/6/2023
TMO Thermo Fisher Scientific	$550.75 0.0%	1/6/2023	Target Raised by	SVB Leerink	-	Outperform	$555.00 -> $620.00	Low	View details for SVB Leerink rating of Thermo Fisher Scientific (NYSE:TMO) on 1/6/2023
WAT Waters	$322.82 -1.2%	1/6/2023	Target Raised by	SVB Leerink	-	Market Perform	$320.00 -> $352.00	Low	View details for SVB Leerink rating of Waters (NYSE:WAT) on 1/6/2023
FATE Fate Therapeutics	$6.29 +2.9%	1/6/2023	Target Lowered by	SVB Leerink	-	Outperform	$62.00 -> $10.00	N/A	View details for SVB Leerink rating of Fate Therapeutics (NASDAQ:FATE) on 1/6/2023
IPSC Century Therapeutics	$4.30 -3.4%	1/6/2023	Target Lowered by	SVB Leerink	-	Outperform	$20.00 -> $14.00	Low	View details for SVB Leerink rating of Century Therapeutics (NASDAQ:IPSC) on 1/6/2023
GRPH Graphite Bio	$3.02	1/6/2023	Downgraded by	SVB Leerink	Analyst M. Foroohar	Outperform -> Market Perform	$11.00 -> $2.00	Low	View details for SVB Leerink rating of Graphite Bio (NASDAQ:GRPH) on 1/6/2023
AMED Amedisys	$93.68 -0.2%	1/5/2023	Target Lowered by	SVB Leerink	-	Market Perform	$96.00 -> $85.00	Low	View details for SVB Leerink rating of Amedisys (NASDAQ:AMED) on 1/5/2023
COGT Cogent Biosciences	$5.88 -7.8%	1/5/2023	Target Raised by	SVB Leerink	-	Outperform	$18.00 -> $20.00	Low	View details for SVB Leerink rating of Cogent Biosciences (NASDAQ:COGT) on 1/5/2023
PGNY Progyny	$40.44 +0.2%	1/5/2023	Reiterated by	SVB Leerink	Analyst S. Davis	Outperform -> Market Perform	$59.00 -> $34.00	Low	View details for SVB Leerink rating of Progyny (NASDAQ:PGNY) on 1/5/2023
PHR Phreesia	$27.91 +3.3%	1/5/2023	Target Raised by	SVB Leerink	Analyst S. Davis	Outperform	$34.00 -> $39.00	Low	View details for SVB Leerink rating of Phreesia (NYSE:PHR) on 1/5/2023
DCPH Deciphera Pharmaceuticals	$15.73 +11.0%	1/4/2023	Target Raised by	SVB Leerink	-	Outperform	$25.00 -> $28.00	Low	View details for SVB Leerink rating of Deciphera Pharmaceuticals (NASDAQ:DCPH) on 1/4/2023
AMGN Amgen	$291.12 -1.3%	12/22/2022	Target Raised by	SVB Leerink	-	Market Perform	$256.00 -> $282.00	Low	View details for SVB Leerink rating of Amgen (NASDAQ:AMGN) on 12/22/2022
RCKT Rocket Pharmaceuticals	$29.50 +0.8%	12/22/2022	Target Lowered by	SVB Leerink	-	Outperform	$54.00 -> $50.00	Low	View details for SVB Leerink rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 12/22/2022
MDGL Madrigal Pharmaceuticals	$189.88 +10.8%	12/20/2022	Target Raised by	SVB Leerink	-	Outperform	$145.00 -> $315.00	Low	View details for SVB Leerink rating of Madrigal Pharmaceuticals (NASDAQ:MDGL) on 12/20/2022
NAMS NewAmsterdam Pharma	$20.45 +4.5%	12/20/2022	Initiated by	SVB Leerink	Analyst R. Ruiz	Outperform	$19.00	Low	View details for SVB Leerink rating of NewAmsterdam Pharma (NASDAQ:NAMS) on 12/20/2022
PCVX Vaxcyte	$74.81 +0.9%	12/16/2022	Reiterated by	SVB Leerink	Analyst D. Risinger	Outperform	$60.00	Low	View details for SVB Leerink rating of Vaxcyte (NASDAQ:PCVX) on 12/16/2022
HCA HCA Healthcare	$306.32 +0.3%	12/16/2022	Target Raised by	SVB Leerink	-	Outperform	$238.00 -> $286.00	Low	View details for SVB Leerink rating of HCA Healthcare (NYSE:HCA) on 12/16/2022
LLY Eli Lilly and Company	$740.16 +0.6%	12/16/2022	Target Raised by	SVB Leerink	-	Outperform	$384.00 -> $410.00	Low	View details for SVB Leerink rating of Eli Lilly and Company (NYSE:LLY) on 12/16/2022
ROIV Roivant Sciences	$10.81 +2.3%	12/19/2022	Target Raised by	SVB Leerink	-	Outperform	$8.00 -> $10.00	Low	View details for SVB Leerink rating of Roivant Sciences (NASDAQ:ROIV) on 12/19/2022
KYMR Kymera Therapeutics	$37.21 +9.5%	12/15/2022	Target Raised by	SVB Leerink	Analyst M. Kratky	Market Perform	$26.00 -> $31.00	Low	View details for SVB Leerink rating of Kymera Therapeutics (NASDAQ:KYMR) on 12/15/2022
WVE Wave Life Sciences	$4.10 +1.0%	12/14/2022	Target Raised by	SVB Leerink	Analyst M. Foroohar	Market Perform	$2.00 -> $7.00	Low	View details for SVB Leerink rating of Wave Life Sciences (NASDAQ:WVE) on 12/14/2022
MRTX Mirati Therapeutics	$58.70 -0.2%	12/14/2022	Target Lowered by	SVB Leerink	-	Outperform	$85.00 -> $75.00	Low	View details for SVB Leerink rating of Mirati Therapeutics (NASDAQ:MRTX) on 12/14/2022
MIRM Mirum Pharmaceuticals	$27.98 +3.6%	12/14/2022	Target Raised by	SVB Leerink	-	Outperform	$49.00 -> $50.00	Low	View details for SVB Leerink rating of Mirum Pharmaceuticals (NASDAQ:MIRM) on 12/14/2022
MRNA Moderna	$87.41 -6.7%	12/13/2022	Target Raised by	SVB Leerink	Analyst M. Foroohar	Market Perform	$101.00 -> $102.00	Low	View details for SVB Leerink rating of Moderna (NASDAQ:MRNA) on 12/13/2022
NRIX Nurix Therapeutics	$8.85 +2.7%	12/13/2022	Target Lowered by	SVB Leerink	-	Outperform	$37.00 -> $28.00	Low	View details for SVB Leerink rating of Nurix Therapeutics (NASDAQ:NRIX) on 12/13/2022
SPRY ARS Pharmaceuticals	$7.08 +9.1%	12/13/2022	Initiated by	SVB Leerink	Analyst Roanna Ruiz	Outperform	$14.00	Low	View details for SVB Leerink rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 12/13/2022
FATE Fate Therapeutics	$6.29 +2.9%	12/13/2022	Target Lowered by	SVB Leerink	-	Outperform	$64.00 -> $62.00	Low	View details for SVB Leerink rating of Fate Therapeutics (NASDAQ:FATE) on 12/13/2022
BGNE BeiGene	$146.98 +2.9%	12/12/2022	Target Raised by	SVB Leerink	-	Outperform	$210.00 -> $236.00	Low	View details for SVB Leerink rating of BeiGene (NASDAQ:BGNE) on 12/12/2022
AFMD Affimed	$0.55 +3.2%	12/12/2022	Target Lowered by	SVB Leerink	-	Outperform	$10.00 -> $6.00	Low	View details for SVB Leerink rating of Affimed (NASDAQ:AFMD) on 12/12/2022
DSGN Design Therapeutics	$2.32 +1.3%	12/9/2022	Target Lowered by	SVB Leerink	-	Outperform	$30.00 -> $22.00	Low	View details for SVB Leerink rating of Design Therapeutics (NASDAQ:DSGN) on 12/9/2022
PHR Phreesia	$27.91 +3.3%	12/9/2022	Upgraded by	SVB Leerink	Analyst Stephanie Davis	Market Perform -> Outperform	$31.00 -> $34.00	Low	View details for SVB Leerink rating of Phreesia (NYSE:PHR) on 12/9/2022
MRTX Mirati Therapeutics	$58.70 -0.2%	12/8/2022	Target Lowered by	SVB Leerink	-	Outperform	$102.00 -> $85.00	Low	View details for SVB Leerink rating of Mirati Therapeutics (NASDAQ:MRTX) on 12/8/2022
REPL Replimune Group	$7.76 +0.5%	12/7/2022	Target Raised by	SVB Leerink	-	Outperform	$30.00 -> $34.00	Low	View details for SVB Leerink rating of Replimune Group (NASDAQ:REPL) on 12/7/2022
GOSS Gossamer Bio	$0.87 +1.0%	12/7/2022	Target Lowered by	SVB Leerink	-	Outperform	$15.00 -> $10.00	Low	View details for SVB Leerink rating of Gossamer Bio (NASDAQ:GOSS) on 12/7/2022

RCKT Rocket Pharmaceuticals	$29.50 +0.8%	12/6/2022	Target Lowered by	SVB Leerink	-	Outperform	$56.00 -> $54.00	Low	View details for SVB Leerink rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 12/6/2022
VEEV Veeva Systems	$216.76 +0.6%	12/2/2022	Target Lowered by	SVB Leerink	-	Outperform	$242.00 -> $233.00	Low	View details for SVB Leerink rating of Veeva Systems (NYSE:VEEV) on 12/2/2022
NTLA Intellia Therapeutics	$28.23 +2.8%	12/2/2022	Target Lowered by	SVB Leerink	-	Outperform	$90.00 -> $86.00	Low	View details for SVB Leerink rating of Intellia Therapeutics (NASDAQ:NTLA) on 12/2/2022
LNTH Lantheus	$56.14 +1.0%	11/30/2022	Initiated by	SVB Leerink	-	Outperform		Low	View details for SVB Leerink rating of Lantheus (NASDAQ:LNTH) on 11/30/2022
FUSN Fusion Pharmaceuticals	$11.57 +2.2%	11/30/2022	Initiated by	SVB Leerink	Analyst Faisal Khurshid	Outperform	$6.00	Low	View details for SVB Leerink rating of Fusion Pharmaceuticals (NASDAQ:FUSN) on 11/30/2022
OABI OmniAb	$5.44 +2.4%	11/29/2022	Initiated by	SVB Leerink	Analyst Puneet Souda	Outperform	$6.00	Low	View details for SVB Leerink rating of OmniAb (NASDAQ:OABI) on 11/29/2022
AXSM Axsome Therapeutics	$96.89 +1.3%	11/29/2022	Target Raised by	SVB Leerink	-	Outperform	$65.00 -> $85.00	Low	View details for SVB Leerink rating of Axsome Therapeutics (NASDAQ:AXSM) on 11/29/2022
ARWR Arrowhead Pharmaceuticals	$32.56 +5.5%	11/29/2022	Target Lowered by	SVB Leerink	-	Market Perform	$33.00 -> $31.00	Low	View details for SVB Leerink rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 11/29/2022
FATE Fate Therapeutics	$6.29 +2.9%	11/24/2022	Target Set by	SVB Leerink	-		$64.00	Low	View details for SVB Leerink rating of Fate Therapeutics (NASDAQ:FATE) on 11/24/2022
ACLX Arcellx	$64.89 +5.4%	11/24/2022	Target Lowered by	SVB Leerink	-		$35.00	Low	View details for SVB Leerink rating of Arcellx (NASDAQ:ACLX) on 11/24/2022
TRVI Trevi Therapeutics	$1.64 +8.6%	11/22/2022	Initiated by	SVB Leerink	Analyst T. Smith	Outperform	$6.00	Low	View details for SVB Leerink rating of Trevi Therapeutics (NASDAQ:TRVI) on 11/22/2022
ARVN Arvinas	$49.89 +3.3%	11/22/2022	Target Lowered by	SVB Leerink	-	Outperform	$89.00 -> $74.00	Low	View details for SVB Leerink rating of Arvinas (NASDAQ:ARVN) on 11/22/2022
SGRY Surgery Partners	$33.70 +2.6%	11/22/2022	Target Lowered by	SVB Leerink	Analyst W. Mayo	Outperform	$55.00 -> $40.00	Low	View details for SVB Leerink rating of Surgery Partners (NASDAQ:SGRY) on 11/22/2022
A Agilent Technologies	$133.34 -0.5%	11/22/2022	Target Raised by	SVB Leerink	-	Outperform	$145.00 -> $160.00	Low	View details for SVB Leerink rating of Agilent Technologies (NYSE:A) on 11/22/2022
ALPN Alpine Immune Sciences	$29.04 +2.2%	11/21/2022	Initiated by	SVB Leerink	Analyst T. Smith	Outperform	$15.00	Low	View details for SVB Leerink rating of Alpine Immune Sciences (NASDAQ:ALPN) on 11/21/2022
TWST Twist Bioscience	$38.19 +4.6%	11/21/2022	Target Lowered by	SVB Leerink	-	Market Perform	$45.00 -> $30.00	Low	View details for SVB Leerink rating of Twist Bioscience (NASDAQ:TWST) on 11/21/2022
EDIT Editas Medicine	$7.45 +3.9%	11/17/2022	Target Lowered by	SVB Leerink	Analyst R. Bienkowski	Market Perform	$14.00 -> $7.00	Low	View details for SVB Leerink rating of Editas Medicine (NASDAQ:EDIT) on 11/17/2022
TBPH Theravance Biopharma	$8.58 +4.4%	11/17/2022	Target Raised by	SVB Leerink	-	Outperform	$12.00 -> $14.00	Low	View details for SVB Leerink rating of Theravance Biopharma (NASDAQ:TBPH) on 11/17/2022
COGT Cogent Biosciences	$5.88 -7.8%	11/17/2022	Target Lowered by	SVB Leerink	-	Outperform	$20.00 -> $18.00	Low	View details for SVB Leerink rating of Cogent Biosciences (NASDAQ:COGT) on 11/17/2022
OLK Olink Holding AB (publ)	$24.22 -0.6%	11/15/2022	Target Raised by	SVB Leerink	-	Outperform	$25.00 -> $27.00	Low	View details for SVB Leerink rating of Olink Holding AB (publ) (NASDAQ:OLK) on 11/15/2022
LNTH Lantheus	$56.14 +1.0%	11/15/2022	Target Raised by	SVB Leerink	-	Outperform	$110.00 -> $120.00	Low	View details for SVB Leerink rating of Lantheus (NASDAQ:LNTH) on 11/15/2022
IPHA Innate Pharma	$2.50 +1.2%	11/15/2022	Target Lowered by	SVB Leerink	-	Outperform	$10.00 -> $9.00	Low	View details for SVB Leerink rating of Innate Pharma (NASDAQ:IPHA) on 11/15/2022
ROIV Roivant Sciences	$10.81 +2.3%	11/15/2022	Target Raised by	SVB Leerink	-	Outperform	$7.00 -> $8.00	Low	View details for SVB Leerink rating of Roivant Sciences (NASDAQ:ROIV) on 11/15/2022
MASS 908 Devices	$7.15 +0.1%	11/15/2022	Target Lowered by	SVB Leerink	-	Outperform	$30.00 -> $25.00	Low	View details for SVB Leerink rating of 908 Devices (NASDAQ:MASS) on 11/15/2022
HARP Harpoon Therapeutics	$22.45 +0.5%	11/15/2022	Target Lowered by	SVB Leerink	-	Outperform	$100.00 -> $40.00	Low	View details for SVB Leerink rating of Harpoon Therapeutics (NASDAQ:HARP) on 11/15/2022
ASND Ascendis Pharma A/S	$141.75 +1.8%	11/14/2022	Target Lowered by	SVB Leerink	-	Outperform	$168.00 -> $148.00	Low	View details for SVB Leerink rating of Ascendis Pharma A/S (NASDAQ:ASND) on 11/14/2022
AIRS AirSculpt Technologies	$7.04 +2.2%	11/14/2022	Target Lowered by	SVB Leerink	-	Outperform	$27.00 -> $8.00	Low	View details for SVB Leerink rating of AirSculpt Technologies (NASDAQ:AIRS) on 11/14/2022
HALO Halozyme Therapeutics	$35.49 +0.7%	11/14/2022	Target Raised by	SVB Leerink	-	Outperform	$52.00 -> $62.00	Low	View details for SVB Leerink rating of Halozyme Therapeutics (NASDAQ:HALO) on 11/14/2022
IFRX InflaRx	$1.52 -3.8%	11/9/2022	Reiterated by	SVB Leerink	Analyst J. Schwartz	Outperform		Low	View details for SVB Leerink rating of InflaRx (NASDAQ:IFRX) on 11/9/2022
PRVA Privia Health Group	$20.89 +2.9%	11/11/2022	Target Lowered by	SVB Leerink	-	Outperform	$46.00 -> $39.00	Low	View details for SVB Leerink rating of Privia Health Group (NASDAQ:PRVA) on 11/11/2022
PEPG PepGen	$14.66 -2.8%	11/10/2022	Target Lowered by	SVB Leerink	Analyst J. Schwartz	Outperform	$40.00 -> $33.00	Low	View details for SVB Leerink rating of PepGen (NASDAQ:PEPG) on 11/10/2022
FDMT 4D Molecular Therapeutics	$28.63 +6.4%	11/10/2022	Target Raised by	SVB Leerink	Analyst M. Foroohar	Market Perform	$10.00 -> $11.00	Low	View details for SVB Leerink rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 11/10/2022
GMAB Genmab A/S	$27.84 +0.2%	11/10/2022	Target Raised by	SVB Leerink	-	Market Perform	$33.00	Low	View details for SVB Leerink rating of Genmab A/S (NASDAQ:GMAB) on 11/10/2022
ARWR Arrowhead Pharmaceuticals	$32.56 +5.5%	11/10/2022	Target Raised by	SVB Leerink	-	Market Perform	$32.00 -> $33.00	Low	View details for SVB Leerink rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 11/10/2022
MREO Mereo BioPharma Group	$4.00 -0.5%	11/10/2022	Target Lowered by	SVB Leerink	-	Outperform	$8.00 -> $4.00	Low	View details for SVB Leerink rating of Mereo BioPharma Group (NASDAQ:MREO) on 11/10/2022
IONS Ionis Pharmaceuticals	$51.40 +2.8%	11/10/2022	Target Lowered by	SVB Leerink	-	Market Perform	$30.00 -> $26.00	Low	View details for SVB Leerink rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 11/10/2022
BGNE BeiGene	$146.98 +2.9%	11/10/2022	Target Raised by	SVB Leerink	-	Outperform	$200.00 -> $210.00	Low	View details for SVB Leerink rating of BeiGene (NASDAQ:BGNE) on 11/10/2022
SCPH scPharmaceuticals	$5.38 +5.3%	11/10/2022	Target Raised by	SVB Leerink	Analyst R. Ruiz	Outperform	$11.00 -> $12.00	Low	View details for SVB Leerink rating of scPharmaceuticals (NASDAQ:SCPH) on 11/10/2022
AHCO AdaptHealth	$7.42 +4.4%	11/10/2022	Target Raised by	SVB Leerink	Analyst Whit Mayo	Outperform	$29.00 -> $30.00	Low	View details for SVB Leerink rating of AdaptHealth (NASDAQ:AHCO) on 11/10/2022
SGRY Surgery Partners	$33.70 +2.6%	11/10/2022	Target Lowered by	SVB Leerink	Analyst W. Mayo	Outperform	$57.00 -> $55.00	Low	View details for SVB Leerink rating of Surgery Partners (NASDAQ:SGRY) on 11/10/2022
ZNTL Zentalis Pharmaceuticals	$11.50 -0.3%	11/10/2022	Target Lowered by	SVB Leerink	-	Outperform	$42.00 -> $27.00	Low	View details for SVB Leerink rating of Zentalis Pharmaceuticals (NASDAQ:ZNTL) on 11/10/2022
ACRS Aclaris Therapeutics	$1.23 +4.2%	11/8/2022	Reiterated by	SVB Leerink	Analyst T. Smith	Outperform		Low	View details for SVB Leerink rating of Aclaris Therapeutics (NASDAQ:ACRS) on 11/8/2022
NEO NeoGenomics	$14.36 -1.0%	11/9/2022	Target Raised by	SVB Leerink	-	Outperform	$12.00 -> $15.00	Low	View details for SVB Leerink rating of NeoGenomics (NASDAQ:NEO) on 11/9/2022
RCM R1 RCM	$10.45 -1.1%	11/9/2022	Target Lowered by	SVB Leerink	-	Outperform	$35.00 -> $16.00	Low	View details for SVB Leerink rating of R1 RCM (NASDAQ:RCM) on 11/9/2022
TALK Talkspace	$2.45	11/9/2022	Target Lowered by	SVB Leerink	-	Market Perform	$2.00 -> $1.00	Low	View details for SVB Leerink rating of Talkspace (NASDAQ:TALK) on 11/9/2022
ABCL AbCellera Biologics	$5.11 +1.8%	11/9/2022	Target Raised by	SVB Leerink	-	Outperform	$13.00 -> $20.00	Low	View details for SVB Leerink rating of AbCellera Biologics (NASDAQ:ABCL) on 11/9/2022
QTRX Quanterix	$24.28 -0.3%	11/9/2022	Target Raised by	SVB Leerink	Analyst P. Souda	Market Perform	$12.00 -> $15.00	Low	View details for SVB Leerink rating of Quanterix (NASDAQ:QTRX) on 11/9/2022
HCAT Health Catalyst	$9.80 +1.0%	11/9/2022	Target Lowered by	SVB Leerink	-	Outperform	$20.00 -> $17.00	Low	View details for SVB Leerink rating of Health Catalyst (NASDAQ:HCAT) on 11/9/2022
MRTX Mirati Therapeutics	$58.70 -0.2%	11/9/2022	Target Lowered by	SVB Leerink	-	Outperform	$111.00 -> $102.00	Low	View details for SVB Leerink rating of Mirati Therapeutics (NASDAQ:MRTX) on 11/9/2022
MNKD MannKind	$3.51 +2.3%	11/9/2022	Target Raised by	SVB Leerink	-	Outperform	$5.00 -> $6.00	Low	View details for SVB Leerink rating of MannKind (NASDAQ:MNKD) on 11/9/2022
HIMS Hims & Hers Health	$9.87 +0.2%	11/8/2022	Upgraded by	SVB Leerink	Analyst J. Zhang	Market Perform -> Outperform	$5.00	Low	View details for SVB Leerink rating of Hims & Hers Health (NYSE:HIMS) on 11/8/2022
TSVT 2seventy bio	$5.99	11/8/2022	Target Lowered by	SVB Leerink	-	Outperform	$42.00 -> $41.00	Low	View details for SVB Leerink rating of 2seventy bio (NASDAQ:TSVT) on 11/8/2022
CLOV Clover Health Investments	$1.02 +2.0%	11/8/2022	Target Lowered by	SVB Leerink	-	Market Perform	$3.00 -> $1.50	Low	View details for SVB Leerink rating of Clover Health Investments (NASDAQ:CLOV) on 11/8/2022
CI The Cigna Group	$334.93 +0.8%	11/8/2022	Target Raised by	SVB Leerink	-	Market Perform	$305.00 -> $335.00	Low	View details for SVB Leerink rating of The Cigna Group (NYSE:CI) on 11/8/2022
BEAM Beam Therapeutics	$29.05 +3.3%	11/7/2022	Target Lowered by	SVB Leerink	-	Outperform	$82.00 -> $81.00	Low	View details for SVB Leerink rating of Beam Therapeutics (NASDAQ:BEAM) on 11/7/2022
ELEV Elevation Oncology	$3.00 +3.4%	11/7/2022	Downgraded by	SVB Leerink	Analyst A. Berens	Outperform -> Market Perform	$11.00 -> $2.00	Low	View details for SVB Leerink rating of Elevation Oncology (NASDAQ:ELEV) on 11/7/2022
ALNY Alnylam Pharmaceuticals	$170.03 +0.3%	11/7/2022	Target Raised by	SVB Leerink	-	Market Perform	$142.00 -> $145.00	Low	View details for SVB Leerink rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 11/7/2022
ALVR AlloVir	$0.72 +7.0%	11/7/2022	Target Raised by	SVB Leerink	-	Outperform	$24.00 -> $25.00	Low	View details for SVB Leerink rating of AlloVir (NASDAQ:ALVR) on 11/7/2022
CRSP CRISPR Therapeutics	$70.01 +1.7%	11/7/2022	Target Raised by	SVB Leerink	-	Outperform	$75.00 -> $76.00	Low	View details for SVB Leerink rating of CRISPR Therapeutics (NASDAQ:CRSP) on 11/7/2022
IMVT Immunovant	$35.50 +0.7%	11/4/2022	Target Raised by	SVB Leerink	-	Outperform	$12.00 -> $14.00	Low	View details for SVB Leerink rating of Immunovant (NASDAQ:IMVT) on 11/4/2022

MarketBeat Community Rating for SVB Leerink

Community Ranking:		2.7 out of 5 ( 2.7 of 5 stars)
Outperform Votes:		22,983 (Vote Outperform)
Underperform Votes:		19,676 (Vote Underperform)
Total Votes:		42,659

MarketBeat's community ratings are surveys of what our community members think about SVB Leerink and other research firms. Vote "Outperform" if you believe SVB Leerink's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SVB Leerink's recommendations will underperform the S&P 500 over the long term. You may vote once every thirty days.

Stock Ratings Reports and Tools

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Ratings for Popular Stocks:

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

SVB Leerink Analyst Recommendations & Stock Picks

MarketBeat Community Rating for SVB Leerink

Stock Ratings Reports and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info